Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results — Barrons.com
By Mackenzie TatananniVera Therapeutics tightened its race against market rivals on Tuesday as the biotechnology company released fresh data for its injectable kidney drug, Trutakna.Late-stage trial results show promise for Trutakna in patients with immunoglobulin A nephropathy, a progressive condi…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.